Latest Whitepapers

Cell culture is essential for a variety of applications including disease modeling, drug discovery, cell-based manufacturing and genetic engineering.

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.

This whitepaper highlights the recent developments and performance of three modular benchtop solutions for the high-performance quantitation and kinetics characterization of proteins and their small molecule interactions.

This whitepaper highlights the features and capabilities of a novel system for streamlining affinity analysis for rapid lead molecule screening.

Rather than choosing between the detail of single-cell RNA sequencing and the in situ capabilities of conventional immunohistochemistry, spatial phenotyping allow you to visualize and quantify dozens of biomarkers in a single tissue sample while maintaining cellular and sub-cellular detail.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Studying the tumor microenvironment (TME) helps improve our understanding of cancer. Myeloid-derived suppressor cells (MDSCs) exist within the TME and maintain cancer progression.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.

While next-generation sequencing is becoming increasingly routine in cancer research laboratories, it fails to address a number of key genomic drivers or markers of cancer, such as structural variations, DNA methylation and transcript isoforms.

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.